Despite the relatively high response rates of MET TKIs in MET exon 14 skipping mutant NSCLC (46-68%) and MET amplified NSCLC (40%) [12–16], acquired resistance is inevitable, a large percentage of patients with targetable MET aberrations fail to respond to MET TKIs, and a subset of MET alterations are untargetable with MET TKIs [17]. The gene discussed is MET; the disease is non-small cell lung carcinoma.